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 Background Data from animal and cell-line models suggest that vitamin D metabolism plays an important role in pancre-
atic tumor behavior. Although vitamin D deficiency has been implicated in numerous cancers, the vitamin D 
status of patients with advanced pancreatic cancer and the effect of baseline vitamin D levels on survival are 
unknown.
 Methods Participants in this correlative study (CALGB 151006) were enrolled in CALGB 80303, which was a randomized 
trial of patients with advanced pancreatic cancer that demonstrated no difference in overall survival (OS) among 
patients treated with gemcitabine plus placebo vs gemcitabine plus bevacizumab. We measured baseline serum 
25-hydroxyvitamin D (25[OH]D) levels and examined associations between baseline 25(OH)D levels and progres-
sion-free survival and OS using the Cox rank score test. All statistical tests were two-sided.
 Results Of 256 patients with available serum, the median 25(OH)D level was 21.7 ng/mL (range 4 to 77). 44.5% of patients 
were vitamin D deficient (25[OH]D <20 ng/mL), and 32.4% were insufficient (25[OH]D ≥20 and <30 ng/mL). 25(OH)
D levels were lower in black patients compared with white patients, and patients of other/undisclosed race (10.7 
vs 22.4 vs 20.9 ng/mL, P < .001). Baseline 25(OH)D levels were not associated with PFS (HR = 1.00, 95% CI = 0.99 
to 1.01, P = .60) or OS (HR = 1.00, 95% CI = 0.99 to 1.01, P = .95).
 Conclusion Vitamin D deficiency was highly prevalent among patients with a new diagnosis of advanced pancreatic cancer. 
Black patients had statistically significantly lower 25(OH)D levels than white patients. In this cohort of patients 
with advanced pancreatic cancer receiving gemcitabine-based chemotherapy, baseline 25(OH)D levels were not 
associated with PFS or OS.
  JNCI J Natl Cancer Inst (2014) 106(8): dju185 doi:10.1093/jnci/dju185
The biologically active form of vitamin D, calcitriol (1,25[OH]2D), 
is a pleiotropic steroid hormone. In addition to its role in calcium 
homeostasis, it affects proliferation and differentiation of many cell 
types, including breast, prostate, and colon cancers (1–4). Its effects 
on pancreatic cancer cells are less well understood, although stud-
ies have reported growth arrest in pancreatic cell lines in response 
to 1,25(OH)2D. In vitro, 1,25(OH)2D analogues inhibit pancreatic 
cancer cell proliferation, induce differentiation, and promote apop-
tosis (5–9). In vivo, they inhibit growth of pancreatic tumor xeno-
grafts in immunodeficient mice (8,10).
Scientific observations from animal and cell-line models on 
pancreatic cancer pathogenesis support the hypothesis that vitamin 
D metabolism is also important in tumor maintenance and may 
contribute in part to this tumor’s chemoresistance. Specifically, the 
vitamin D receptor (VDR) is known to mediate the activity of vita-
min D and has been identified in pancreatic cancer cells (8,11). In 
one study of VDR expression in human pancreatic cancer cell lines, 
it was established that VDR expression was increased more than 
threefold compared with that in normal pancreatic cells (12). Both 
normal and malignant pancreatic cells express 1-α-hydroxylase, 
the enzyme that converts plasma 25(OH)D into its bioactive form 
1,25-dihydroxycholecalciferol (1,25[OH]2D) (11,13,14).
Recent data from two genome-wide analysis studies (GWAS) 
point to the role of the VDR and vitamin D pathway in patients 
with pancreatic adenocarcinoma. GWAS performed on a cohort 
of patients enrolled on Cancer and Leukemia Group B (CALGB) 
80303 and on patients included in the Pancreatic Cancer Cohort 
Consortium (PanScan) identified one VDR single-nucleotide poly-
morphism (SNP) that associates with better overall survival (OS) 
(15).
To our knowledge, no study has previously investigated whether 
vitamin D concentration is predictive of survival following a diag-
nosis with pancreatic cancer. We examined the cohort of partici-
pants in CALGB 80303 who had advanced pancreatic cancer and 
received systemic chemotherapy in the context of this randomized 
clinical trial. We aimed to describe the prevalence of vitamin D 
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Participants in this correlative study (CALGB 151006)  were 
enrolled in CALGB 80303, which was a national, multi-center, 
double-blind phase III study that randomly assigned patients (1:1) 
with advanced pancreatic cancer to gemcitabine plus bevacizumab 
vs gemcitabine plus placebo. Full details of the trial and results 
were previously published (16). Eligible patients had unresectable 
adenocarcinoma of the pancreas and had received no prior therapy 
for metastatic disease (prior radiation and/or chemotherapy in the 
adjuvant setting were allowed). A  baseline Eastern Cooperative 
Oncology Group (ECOG) performance status of 0 to 2 and ade-
quate renal, liver, and bone marrow function were required.
Patients signed informed consent for participation in the thera-
peutic trial and were given the option to sign a secondary consent 
for a companion study for biomarker research. This correlative 
study was approved by the UCSF Committee for Human Research 
(IRB Number 10-04423).
In total, 602 patients were enrolled in CALGB 80303, and 
535 were treated. Three hundred and fifty-two patients provided 
optional consent for collection of blood and urine specimens, of 
whom 274 had serum available in storage. Figure 1 illustrates the 
derivation of the final cohort size (n = 256) and reasons for exclusion 
at various time points. Among the 535 patients treated on study, the 
median OS was 5.8 months in the gemcitabine plus bevacizumab 
arm and 5.9  months in the gemcitabine plus placebo arm. With 
respect to the primary outcome, consented patients with available 
serum samples were representative of the larger study population 
with similar median OS (5.9 vs 5.8 months, respectively).
Response and Progression Criteria
Study enrollment required documentation of disease extent by CT 
scan prior to initiation of therapy. Patients were evaluated every 
eight weeks for response, which was assessed through conventional 
RECIST criteria. Progression-free survival (PFS) was calculated 
as time from study enrollment to disease progression or death. 
OS was calculated as the time from registration to death from any 
cause.
Serum Biomarker Assessment
Blood samples were collected from consenting participants in 
CALGB 80303 at the time of study registration at respective insti-
tutions and shipped to the CALGB Pathology Coordinating Office 
for storage (Columbus, OH). For processing of the 25(OH)D 
assay, 150 microliters of available serum specimens were placed 
into Sarstedt #72.730 cryovials and shipped on dry ice to Heartland 
Assays, Inc. (Ames, IA). It has been previously established that 
25(OH)D results obtained for patients are unaffected by multiple 
freeze-thaw cycles (17).
The method for quantitative determination of 25(OH)D was 
a Food and Drug Administration-approved direct, competitive 
chemiluminescence immunoassay using the DiaSorin© LIAISON 
25-OH Vitamin D Total assay (18,19). This system was selected 
based upon its high sample throughput and equal recognition of 
circulating 25(OH)D2 and 25(OH)D3. All values in our data set 
were above the assay’s minimum detectable concentration of less 
than 2.5 ng/mL (18).
To ensure quality control, 5% of samples were submitted as 
blinded duplicates to verify reproducibility of assay results (n = 13). 
All laboratory personnel were blinded to patient identifiers and 
outcome. The Bland-Altman plot of 13 duplicate specimens is 
displayed in Supplementary Figure 1 (available online). The intra-
class correlation coefficient of the assay was calculated to be 0.97 
(95% CI = 0.91 to 0.99).
Statistical Design and Analysis
Descriptive analyses were performed to report the demographic 
and clinical characteristics. Although there is no consensus regard-
ing optimal physiologic levels, we defined vitamin D levels as they 
are most commonly reported in the literature: vitamin D defi-
ciency was defined as a serum 25(OH)D level less than 20 ng/mL, 
insufficiency as 20 to 29 ng/mL, and sufficiency as 30 ng/mL and 
greater (20). The association between vitamin D levels and patient 
characteristics was described with medians and ranges and com-
pared using the Wilcoxon rank sum test (21). The cut point for age 
(<70 and ≥70 years) is an optimized value determined by a recur-
sive partitioning approach (22). The cut point for body-mass index 
(BMI) (<25 and ≥25 kg/m2) was determined by the median value. 
























Figure 1. Derivation of cohort size.
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self-reported race was previously reported in the GWAS of this 
cohort (23). To address the possibility of reporting bias for the 
self-reported variable of race, analyses were also performed on 
the subset of patients with available GWAS data on genetically 
estimated race.
The primary statistical objective was to investigate the associa-
tion between 25(OH)D level and OS. The association was tested 
using the Cox rank score test, using 25(OH)D as a continuous 
variable (eg, per each incremental increase of 1 ng/mL) (24). Serum 
25(OH)D levels were defined in four quartiles, with almost equal 
numbers of patients in each. Chi-square tests were used to com-
pare the impact of demographic and clinical characteristics across 
quartiles (25). The distributions of OS and PFS were also com-
pared between the subgroups of patients with extreme low 25(OH)
D levels (<10 ng/mL) and “optimal” levels (≥36 ng/mL) (26) using 
a log rank test (27).
In secondary analyses, tests of interaction between serum 
25(OH)D and potential effect modifiers were assessed by entering 
in the model 25(OH)D as a continuous variable with covariates as 
either continuous or binary variables. Geographic latitude as deter-
mined by home zipcode was tested both as a binary variable and as 
a continuous variable; the Kendall’s rank correlation test was used 
to test latitude as a continuous variable (21). Additional exploratory 
analyses using the Cox proportional hazards model and ensemble 
methods (eg, random forests) were employed (22,28). Differences 
in 25(OH)D levels among racial populations were tested using the 
Kruskal-Wallis test (29). The reported P values and confidence 
intervals are two sided and not adjusted for multiple testing.
All analyses were performed using R software (version 3.0.1) 
and extension packages for survival (version 2.37–4), party (version 
1.0–8), and zipcode (version 1.0) (22,30–32). The intraclass cor-
relation coefficient of the 25(OH)D assay was calculated using the 
ICC function of the irr extension package (33). Data collection and 
statistical analyses were conducted by the Alliance Statistics and 
Data Center. All analyses were based on the study database frozen 
on June 9, 2009.
results
Patient Characteristics
Baseline characteristics of the 256 included patients are displayed 
in Table 1. The median age at diagnosis was 64 years (range 35 to 
Table 1. Relationship of 25(OH)D levels to selected patient characteristics
Characteristic No. patients (%)
Median 25(OH)D, 
ng/mL (range) P
Age at diagnosis, y*
 <70 182 (71.1) 21.4 (4.0–50.2) >.15
 ≥70 74 (28.9) 22.4 (5.3–77.0)
Sex
 Female 120 (46.9) 20.8 (4–47) >.07
 Male 136 (53.1) 22.5 (4–77)
Race
 White 225 (87.9) 22.4 (4–77) <.001
 Black 23 (9.0) 10.7 (4.0–36.3)
 Other/Unknown 8 (3.1) 20.9 (12.6–31.8)
BMI, kg/m2†
 <25 126 (49.2) 21.6 (4.0–71.2) >.47
 ≥25 130 (50.8) 22.3 (4.2–77)
ECOG PS
 0
 1 234 (91.4) 22.1 (4–77) >.18
 2 22 (8.6) 18.8 (4–42.4)
Extent of disease
 Locally advanced 217 (84.8) 21.3 (4–77) >.17
 Metastatic 39 (15.2) 22.6 (9.5–71.2)
Prior radiation
 No 225 (87.9) 22 (4–77) >.12
 Yes 31 (12.1) 17.1 (7.5–40.8)
Prior chemotherapy
 No 223 (87.1) 22 (4–77) >.16‡
 Yes 28 (10.9) 16.55 (7.5–40.8)
 Unknown 5 (2.0)  24.9 (5.9–33.1)
Geographic latitude
 <40° 119 (46.5) 21.9 (4–71.2) >.89‡
 ≥40° 96 (37.5) 20.7 (4.2–43.3)
 Unknown 41 (16) 21.3 (9.5–77)
* Cut point is an optimized values decided by using recursive partitioning approach. 25(OH)D = 25-hydroxyvitamin D3; BMI=Body-mass index; ECOG PS = Eastern 
Cooperative Oncology Group Performance Status.
† Body-mass index is calculated as weight (kilograms) divided by height (meters) squared. Values reflect patient status at time of initiation of chemotherapy (clinical 
trial enrollment). Cut point is the median value.
‡ Comparison did not include the Unknown group.
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84). 29% of participants were 70 years or older, 53% were men, 
and 88% were self reported as white. GWAS data on genetic race 
was available for 211 of 256 participants; of these, genetic race was 
reported as white for 187 (88%), black for 14 (6.6%), and unknown 
for 10 (4.7%).
Distribution of 25(OH)D Levels
The median serum 25(OH)D level for the entire cohort was 
21.7 ng/mL (range 4 to 77). At time of specimen collection prior 
to initiation of chemotherapy, 44.5% of patients were vitamin D 
deficient (25[OH]D <20 ng/mL), and 32.4% were insufficient 
(25[OH]D ≥20 and <30 ng/mL). Only 23% of patients had serum 
25(OH)D levels above the threshold for vitamin D sufficiency 
(≥30 ng/mL). Figure  2 summarizes the distribution of serum 
25(OH)D levels.
Association of 25(OH)D Levels With Patient 
Characteristics
Among 256 patients with available serum, 25(OH)D levels were 
lower in patients self-reported as black (median 10.7 ng/mL) com-
pared with white patients (median 22.4 ng/mL) and patients of 
other or undisclosed race (median 20.9 ng/mL) (P < .001). Vitamin 
D deficiency was more common among self-reported black patients 
(82.6%) compared with white patients (40.9%) and those of other 
or undisclosed race (37.5%). Moreover, only 4.3% of blacks, 25.3% 
of whites, and 12.5% of patients of other or undisclosed race dem-
onstrated serum 25(OH)D levels in a sufficient range. Boxplots of 
25(OH)D measurements according to race are shown in Figure 3. 
Among the 211 patients for whom both serum and GWAS data 
on race were available, 25(OH)D levels according to genetic race 
were comparable to those for self-reported race. 25(OH)D levels 
were statistically significantly lower in genetically black patients 
(median 10.1 ng/mL) than in genetically white patients (median 
22.4 ng/mL) (P < .001).
As shown in Table 1, baseline serum 25(OH)D concentration 
was not statistically significantly associated with patient age, sex, 
BMI, ECOG performance status, extent of disease, prior radiation, 
prior chemotherapy, or geographic latitude (as a binary variable). 
When tested as a continuous variable, geographic latitude was still 
not associated with 25(OH)D levels (P = .95).
In a secondary analysis, patients were grouped into four quar-
tiles of 63 to 65 patients apiece, according to escalating serum 
25(OH)D levels (Quartile 1: 25(OH)D <15.3; Quartile 2: 25(OH)
D ≥15.3 and <21.7 ng/mL; Quartile 3: 25(OH)D ≥21.7 and 
<29 ng/mL; Quartile 4: 25(OH)D ≥29 ng/mL). Groupings were 
not entirely equal because of ties in 25(OH)D levels at cut points. 
We further examined the association of four quartiles of 25(OH)
D levels with potential covariables (Table  2). Again, there was 
no interaction with any covariable except race. This finding was 
reproduced using GWAS data on genetic race for 211 patients (P < 
.001). Of the 23 self-reported black patients included in this study, 
16 (70%) were in the lowest quartile of serum 25(OH)D levels 
and only one (4%) was in the highest quartile. By comparison, the Figure 2. Distribution of serum 25(OH)D levels in the study cohort (n = 256).
Figure 3. Boxplots of 25(OH)D measurements, according to race. Solid horizontal lines represent medians and whiskers represent the ranges.
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white patients included in this study were uniformly represented 
in each quartile.
Relationship of Vitamin D Levels on Patient Outcomes
While only 23% of our cohort had sufficient 25(OH)D levels 
(≥30 ng/mL) at study baseline, we still examined the association 
between baseline levels and patient outcomes, including PFS and 
OS. At the time of this analysis, 254 of 256 patients were deceased, 
with an event rate of 97%. The unadjusted HR for PFS was 1.00 
(95% CI = 0.99 to 1.01, P = .60). The unadjusted HR for OS was 
1.00 (95% CI = 0.99 to 1.01, P =  .95). After adjustment for race, 
baseline 25(OH)D levels were not associated with PFS (HR = 1.00, 
95% CI = 0.99 to 1.01, P = .76) or OS (HR = 1.00, 95% CI = 0.99 
to 1.01, P  =  .97). No statistically significant relationships were 
detected between quartiles of serum 25(OH)D levels and either 
PFS or OS. Kaplan-Meier curves for PFS and OS, according to 
quartile, are displayed in Figure 4.
Patients with serum 25(OH)D levels in the highest quartile had 
a PFS of 3.88 months (95% CI = 3.6 to 5.5 months) and OS of 
5.36 months (95% CI = 4.7 to 8.6 months). Patients with serum 
25(OH)D levels in the lowest quartile had a PFS of 2.56 months 
(95% CI = 2.0 to 4.0) and OS of 5.95 months (95% CI = 4.6 to 
9.1). Based upon the observation of increasing median PFS across 
quartiles (2.56, 2.78, 3.60, and 3.88 months in Quartiles 1, 2, 3, and 
4, respectively), we performed log rank score tests for trend. A long 
rank score test of 25(OH)D level as a continuous variable did not 
demonstrate an association with PFS (P = .60). No association for 
PFS was seen by testing 25(OH)D levels according to rank or quar-
tiles (P = .38 and P = .19, respectively).
Among the 34 patients with levels of 25(OH)D defined as 
physiologically “optimal” (≥36 ng/mL) (26), the median PFS was 
3.84 months (95% CI = 2.0 to 4.9) and median OS was 4.99 months 
(95% CI = 3.98 to 8.05). Among patients with extreme low levels 
(<10 ng/mL), the median PFS was 1.99 (95% CI = 1.61 to 4.57) 
and median OS was 4.80 months (95% CI = 3.42 to 9.13). When 
the subgroups with extreme high or low levels were compared, no 
statistically significant differences in PFS (P = .48) or OS (P = .79) 
were seen.
Table 2. Characteristics of study cohort according to quartile of serum 25(OH)D (n = 256)*
 Characteristic
Serum 25(OH)D
Quartile 1 Quartile 2 Quartile 3 Quartile 4
N = 63 N = 64 N = 64 N = 65 P
Serum 25(OH)D, ng/mL
 Mean 10.6 18.0 24.8 37.8 <.001
Age at diagnosis, y
 Mean 61.8 65.4 62.9 64.6 .19
BMI, kg/m2
 Mean 26 26 28 26 .98
Sex, No.
 Female 37 26 30 27
 Male 26 38 34 38 .15
Race or ethnicity, No.
 White 46 56 60 63
 Black 16 4 2 1
 Other/unknown 1 4 2 1 <.001
ECOG PS, No.
 0
 1 56 56 62 60
 2 7 8 2 5 .23
Extent of disease, No.
 Metastatic 56 55 54 52
 Locally advanced 7 9 10 13 .56
Prior radiation, No.
 No 55 54 56 60
 Yes 8 10 8 5 .58
Prior chemotherapy, No.
 No 52 56 55 60
 Yes 9 8 7 4 .48†
 Unknown 2 0 2 1
Geographic latitude, No.
 <40° 34 23 32 30
 ≥40° 20 29 23 24 .26†
 Unknown 9 12 9 11
* Body mass index is calculated as weight (kilograms) divided by height (meters) squared. Values reflect patient status at time of initiation of chemotherapy (clinical 
trial enrollment). Quartile 1: 25(OH)D<15.3 ng/mL; Quartile 2: 25(OH)D ≥15.3 and <21.7 ng/mL; Quartile 3: 25(OH)D ≥21.7 and <29 ng/mL; Quartile 4: 25(OH)D 
≥29 ng/mL. 25(OH)D = 25-hydroxyvitamin D3; BMI = body mass index; ECOG PS = Eastern Cooperative Oncology Group Performance Status.
† Comparison did not include the Unknown group.
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Discussion
This study is the first to characterize the vitamin D status of patients 
at time of diagnosis with advanced pancreatic cancer and to test 
the association between 25(OH)D levels and OS. In the cohort 
of patients we studied, 44.5% were vitamin D deficient (<20 ng/
mL) and 22.5% were vitamin D insufficient (<30 ng/mL). Among 
patients self-reported as black, serum 25(OH)D levels were statis-
tically significantly lower than in patients self-reported as white. 
However, low vitamin D levels were not associated with diminished 
OS or PFS.
The high prevalence of vitamin D insufficiency in our cohort 
is consistent with reports from cohorts of patients with breast 
cancer and metastatic colorectal cancer. A recent study of women 
with stages I-III breast cancer, which included a high proportion 
of black and Hispanic women, reported that 74% of women were 
deficient at baseline and also found that supplementation using 
standard dosing guidelines was inadequate to increase 25(OH)
D levels to a normal range (34). In a cohort of 515 patients with 
metastatic colorectal cancer, 50% were vitamin D deficient, and 
an additional 32% were insufficient (35). In both of these cohorts, 
25(OH)D levels were lower in black patients compared with white 
patients and patients of other race (34,35).
Low vitamin D levels are not unique to cancer patients, 
however. Among 14 000 individuals who participated in the 
National Health and Nutrition Examination Survey (NHANES) 
III between 2001 and 2004, 77% had 25(OH)D levels less than 
30 ng/mL, with a mean level of 24 ng/mL (36). In comparison 
with the NHANES population, we detected a higher prevalence 
of extreme low serum 25(OH)D levels (<10 ng/mL) in our study 
cohort (9.1% vs 6%).
The apparent propensity toward extreme deficiency in patients 
with advanced pancreatic cancer may reflect malabsorption of this 
fat-soluble vitamin in those with pancreatic exocrine insufficiency. 
However, vitamin D concentration is primarily dependent on endog-
enous production by skin following exposure to ultraviolet rays and, 
to a lesser extent, on dietary consumption of vitamin D (37,38). 
The greater prevalence of vitamin D deficiency among black 
patients in our cohort is consistent with other studies (34–36,39) 
and likely due to reduced vitamin D photosynthesis in pigmented 
skin because of greater melanin content and increased absorption of 
UVB radiation (40). Between 2006 and 2010, black Americans had 
an age-adjusted incidence rate of pancreatic cancer that was 31% 
higher than in white Americans and an age-adjusted mortality rate 
that was 27% higher (41). In the NHANES III cohort, non-His-
panic black race was identified as an independent predictor of pan-
creatic cancer-related mortality (adjusted HR = 2.80, 95% CI = 1.23 
to 6.37) (42). A recent review on racial disparities for a variety of can-
cer types identified pancreatic cancer as one of several cancers where 
increased risk among blacks was not attributable to socioeconomic 
status, cancer stage at diagnosis, or treatment (43). Our data do not 
suggest that racial disparities in survival for patients with advanced 
pancreatic cancer can be explained by 25(OH)D levels alone.
The published data on the prognostic role of circulating 25(OH)
D levels in other cancers are generally sparse and of poor quality. In 
a systematic review of all published studies evaluating the impact 
of baseline 25(OH)D on outcome measures in a multitude of diag-
noses and disease stages, five of eight demonstrated a statistically 
significant negative prognostic role for low 25(OH)D levels, and 
three demonstrated no prognostic role (44). Two studies on early-
stage breast cancer produced conflicting results, and two studies 
Figure 4. A) Progression-free survival (PFS) by quartile of 25(OH)D. B) Overall survival by quartile of 25(OH)D.
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on non-small cell lung cancer reported no prognostic role. Studies 
that demonstrated a prognostic effect of 25(OH)D levels on out-
come measures included a study in melanoma and a smaller study 
in prostate cancer. Two studies in colon cancer reported a prognos-
tic role for 25(OH)D; however, a larger study of 515 clinical trial 
participants was published following this review that showed no 
relationship between 25(OH)D levels and patient outcomes (35).
In the current study, we did not detect an association between 
serum 25(OH)D levels and patient outcome. It is possible that vita-
min D may have a limited impact on the natural history of pancre-
atic cancer given the grim prognosis associated with advanced stage 
disease. On the other hand, our data may underestimate the actual 
prevalence of vitamin D insufficiency associated with advanced pan-
creatic cancer, because CALGB 80303 participants met rigorous 
eligibility criteria (eg, 90% of subjects had an ECOG performance 
status of 0 or 1). This suggests that most patients with advanced 
pancreatic cancer may be vitamin D insufficient, or worse. As 
opposed to studies emanating from single institutions, this analysis 
of patients participating in a National Cancer Institute-sponsored 
trial allowed for assessment of serum 25(OH)D levels in patients 
living at various latitudes across North America. In addition, the 
vitamin D assay that was utilized had high precision.
Nonetheless, potential limitations should be addressed. This 
analysis included a small number of patients who were categorized 
as having sufficient 25(OH)D levels, which may have prevented a 
robust examination of association with outcomes. Baseline 25(OH)
D levels in cancer patients may not represent true steady state but 
rather could reflect inadequate nutrition or limited outdoor activ-
ity as influenced by morbidity from recent illness and/or burden of 
cancer (45). Because this study only performed 25(OH)D measure-
ment on specimens obtained prior to the initiation of gemcitabine-
based chemotherapy, the impact of chemotherapy on vitamin D 
status and its possible effect on patient outcomes could not be 
studied.
In conclusion, we detected a high prevalence of vitamin D insuf-
ficiency among patients with advanced pancreatic cancer undergoing 
gemcitabine-based chemotherapy. We found that vitamin D deficiency 
was pronounced among black patients and substantiated this finding 
using GWAS data for race. This observation suggests the possibil-
ity of a genetic basis for the variability between 25(OH)D levels and 
exposure. While the relative rarity of adequate vitamin D levels in this 
population may preclude detection of an association between higher 
vitamin D levels and patient outcomes, additional inquiry regarding 
genetic factors that may predict for benefit from optimized vitamin D 
status in patients with pancreatic cancer may be considered.
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